India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Dr. Chuanhai Cao has joined its medical research team as a key advisor. “The addition of Dr. Cao will accelerate IGC’s efforts to move its Alzheimer’s product Hyalolex to clinical trials,” Ram Mukunda, CEO of IGC, noted in the news release. “Dr. Cao is a dynamic force in cannabis related therapies for Alzheimer’s disease. Dr. Cao has one co-inventor patent that has been approved for medical trials, and another patent that is currently being worked on for an Investigational New Drug (IND) application with the FDA. Dr. Cao is the perfect researcher to assist us in moving our THC-based Alzheimer’s treatment into trials and potentially into a blockbuster product.” Cao currently serves as associate professor of pharmaceutical sciences at the University of South Florida’s College of Pharmacy. Additionally, he has joint appointments as associate professor at USF’s Department of Neurology at the College of Medicine and the Department of CMMB at the College of Arts and Sciences.
To view the full press release, visit http://nnw.fm/f21oZ
About IGC
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
